Inflexion
Inflexion_25Years
Menu

Healthcare

Healthcare and Life Sciences sector is comprised of businesses which have high levels of IP and technological know-how, mission-driven teams, and potential to become international champions. The rapid pace of change in some areas of technology and molecular biology lends it to entrepreneurial teams and investors like Inflexion.

Shutterstock 2017970447

Sector spotlight: Healthcare

Inflexion's Head of Healthcare Ben Long recently caught up with experienced healthcare executive Jane Griffiths about her long and successful career at J&J and the lessons she has learnt along the way. You can listen to the conversation here. 

Films

Medivet

Rosemont Pharmaceuticals

Investing in healthcare

Portfolio

Filter by

CNX Therapeutics

CNX Therapeutics

Pharmaceuticals

In 2021 Inflexion acquired CNX Therapeutics, a European pharmaceutical company dedicated to the supply of essential medicines. The business was formed when Inflexion acquired Sunovion Pharmaceuticals Europe Limited. View case study

European LifeCare

European LifeCare

Vaccination Services

In 2018 Inflexion invested in European LifeCare, Europe's largest independent provider of travel clinics and public vaccination programmes. View case study

HKI

HKI

Healthcare information services

In 2004 Inflexion acquired public health performance analytics business HKI in a £10m deal. The business was later sold in two parts for an overall return of 2.6x. View case study

ICS

ICS

Temporary staffing solutions

Temporary healthcare staffing business ICS chose to partner with Inflexion in 2008. It was sold 22 months later to Blackstone Group for an overall return on investment of 2.9x. View case study

Lintbells

Lintbells

Supplements for pets

Lintbells is a globally recognised leader in pet supplements. Inflexion invested in the business in 2017, before selling it to Vetnique Labs in 2024. View case study

Medivet

Medivet

Veterinary services

In 2016, Inflexion provided minority funding to support the expansion of Medivet, a UK veterinary pet-care business. A successful partnership delivered strong acquisitive and organic growth, and Medivet was sold in 2021 to CVC Capital Partners. View case study

Pharmaspectra

Pharmaspectra

Medical affairs data

In 2019, Inflexion invested in Pharmaspectra, a leading global provider of medical affairs data to the pharmaceutical and biotech industry. Inflexion exited the business in 2022. View case study

Phlexglobal

Phlexglobal

Clinical research documentation management

Inflexion backed the buyout of TMF services provider Phlexglobal in 2011, supporting its growth until it was sold to Bridgepoint Development Capital in 2014. View case study

Proteros

Proteros

Drug discovery research platform

Proteros Biostructures GmbH is a leading Germany-based founder-led contract research organisation focused on early-stage drug discovery. View case study

Rosemont Pharmaceuticals

Rosemont Pharmaceuticals

Liquid pharmaceuticals

In 2020 Inflexion acquired Rosemont Pharmaceuticals, the UK’s leading liquid pharmaceuticals business. The business was carved out of listed parent company, Perrigo. View case study

SteriPack

SteriPack

Medical device contract designer and manufacturer

SteriPack is a leading global contract manufacturer serving the medical device, pharmaceutical and diagnostic markets. Inflexion led the buyout of SteriPack in 2022. View case study

TPP

TPP

Veterinary platform

In 2024, Inflexion invested in Tierarzt Plus Partner (“TPP”), Germany’s largest group of veterinary practices. View case study

Upperton Pharma Solutions

Upperton Pharma Solutions

Particle engineering for the pharmaceutical industry

In 2022, Inflexion made a substantial investment into Upperton Pharma Solutions, a UK based specialist contract development and manufacturing organisation which has expertise in particle engineering for the pharmaceutical industry. View case study

Village Vets

Village Vets

Veterinary services

Village Vets is the largest independent group of veterinary practices in the Republic of Ireland. Inflexion’s Enterprise Fund invested in the business in 2024 to support management’s ambitions to provide an enhanced offering to its customers through organic and acquisitive growth. View case study

Team

News, insights and events

Articles